Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSenti: Neoadjuvant Pembrolizumab in High-risk Melanoma
NCT07448831Phase 2Recruiting
- Sponsor
- UZ Brussel
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by UZ Brussel. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07448831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448831.